News

GMO acreage reaches new high
Enlarge image

BusinessEUSpainGermanyPoland

GMO acreage reaches new high

21.02.2013 - Global acreage of biotech crops have increased by 6% last year. Europe contributes only 0.075%.

Brussels/Manila - Genetically modified (GM) soybeans, maize, cotton and rapeseed were planted on 170.3 million hectares last year, according to figures from the International Service for the Acquisition of Agri-Biotech Applications (ISAAA). However, the adoption of biotech crops has become slower. After double digit growth rates three years ago, this year the cultivation area increased only by 6 percent or 10.3 million hectares compared to 2011. 

However, Europe remains a minor player in the growing market for GMOs due to public hostility to GMOs. The EU countries grew 129,071 hectares of Bt maize, about 14,000 hectares more than in 2011. Spain remained the leading EU country for GMO acreage with 116,306 hectares in 2012. Poland discontinued the planting of biotech maize.  The US (69.5m ha, +0.7%), Brazil (36.6m ha, +20,8%), Argentina (23.9m ha, +0,8%), Canada (11.6m ha, +11,5), and India (10.6m ha, +1,8%) were the leading GMO producers. Global Adoption of GM soybeans (+8%), cotton (+7%), maize (+4%), and rapeseed (+5%) increased as compared to 2011.  

"There is one principal and overwhelming reason that underpins the trust and confidence of farmers in biotechnology: biotech crops deliver substantial, and sustainable, socio-economic and environmental benefits," stressed ISAAA chief Clive James. In fact, German BASF and Monsanto both filed for US approval of the first drought-tolerant crop last year. However, the US Department of Agriculture recently delayed the approval of new herbicide-tolerant GMOs because weeds are becoming more and more resistant to the herbicide Glyphosate, which is marketed together with Glyphosate-tolerant GMOs since 1996.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/gmo-acreage-reaches-new-high.html

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%
  • ADDEX3.30 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%

TOP

  • BIOFRONTERA2.90 EUR31.8%
  • VITA 344.32 EUR7.2%
  • BB BIOTECH157.70 EUR6.1%

FLOP

  • PAION2.24 EUR-27.7%
  • CYTOS0.16 CHF-23.8%
  • MAGFORCE5.90 EUR-16.9%

TOP

  • SANTHERA85.50 CHF2288.3%
  • CO.DON2.75 EUR183.5%
  • PAION2.24 EUR143.5%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 24.10.2014